Literature DB >> 15189187

Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.

Tânia S Andrade1, Luiz G M Castro, Ricardo S Nunes, Viviane M F Gimenes, Arlete E Cury.   

Abstract

Fourteen Fonsecaea pedrosoi isolates from six chromoblastomycosis patients were submitted to susceptibility testing. Some patients were undergoing treatment with itraconazole (ITZ) and/or cryosurgery with liquid nitrogen. The antifungal agents amphotericin B (AMB), ITZ, fluconazole (FCZ), ketoconazole (KCZ), 5-fluorocytosine (5-FC), and terbinafine (TBF) were tested. AMB and FCZ showed less activity for all isolates. The most active agents were KCZ and TBF. Sequentially isolates from four patients presented ITZ minimal inhibitory concentration (MIC) higher than the previous ones; for two of these patients, response to therapy with this agent was not observed. These results suggest development of microbiologic resistance to ITZ in four instances, two of them coinciding with lack of clinical response to this drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189187     DOI: 10.1111/j.1439-0507.2004.00984.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  16 in total

1.  Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro.

Authors:  Yongxuan Hu; Xiaowen Huang; Sha Lu; Michael R Hamblin; Eleftherios Mylonakis; Junmin Zhang; Liyan Xi
Journal:  Mycopathologia       Date:  2014-11-01       Impact factor: 2.574

2.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

Review 3.  Black yeasts and their filamentous relatives: principles of pathogenesis and host defense.

Authors:  Seyedmojtaba Seyedmousavi; Mihai G Netea; Johan W Mouton; Willem J G Melchers; Paul E Verweij; G Sybren de Hoog
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 5.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

Authors:  Mohammad J Najafzadeh; Hamid Badali; Maria Teresa Illnait-Zaragozi; G Sybren De Hoog; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

7.  In vitro antifungal activity of naftifine hydrochloride against dermatophytes.

Authors:  M Ghannoum; N Isham; A Verma; S Plaum; A Fleischer; B Hardas
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

8.  Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

Authors:  S Deng; W Lei; G S de Hoog; L Yang; R G Vitale; H Rafati; M Seyedmousavi; A Tolooe; H van der Lee; W Liao; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 9.  Challenges in the therapy of chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Daniel Wagner de C L Santos
Journal:  Mycopathologia       Date:  2013-05-02       Impact factor: 2.574

Review 10.  Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics.

Authors:  Sha Lu; Changming Lu; Junmin Zhang; Yongxuan Hu; Xiqing Li; Liyan Xi
Journal:  Mycopathologia       Date:  2012-10-20       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.